Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
The list of drug companies forced into several hundred million dollar settlements for making fraudulent product claims continues to lengthen. And the signs are that the US government will continue to ramp up its efforts, using new theories of liability and handing out even stiffer penalties. Mark Ratner investigates.
Action needs to be taken to prevent anti-biotech activists from co-opting environmental law to derail the planting of transgenic crops that have already received regulatory approval.
The antiquated legal standard that natural laws and products are not eligible for patent protection is ill-suited for gene and diagnostics patents. Here, I propose a new, technology-agnostic framework for determining patent eligibility that is tailored to the meet the US Constitutional objective of promoting innovation.
Only one drug targeting the proteasome protein degradation pathway has been approved, but several second-generation inhibitors are making progress in trials. Jim Kling reports.
First-generation epigenetic drugs have proven clinically useful in several hematological cancers. But newer enzyme inhibitors in the pipeline aim to be more selective and promise to broaden the portfolio of therapeutic uses.
Claims of conflicts of interest concerning authorship of a scientific paper highlight the difficulties facing regulators participating in collaborations with industry.